Applicability and Cost Implications for Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors Based on the ODYSSEY Outcomes Trial: Insights From the Department of Veterans Affairs

Salim S. Virani*, Julia M. Akeroyd, Vijay Nambi, Erin D. Michos, Pamela B. Morris, Khurram Nasir, Sidney C. Smith, Neil J. Stone, Laura A. Petersen, Christie M. Ballantyne

*Corresponding author for this work

Research output: Contribution to journalLetterpeer-review

12 Scopus citations
Original languageEnglish (US)
Pages (from-to)410-412
Number of pages3
Issue number3
StatePublished - Jan 15 2019


  • cholesterol
  • clinical trial

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Cite this